Literature DB >> 9600322

Opsonophagocytic and bactericidal activity mediated by purified IgG subclass antibodies after vaccination with the Norwegian group B meningococcal vaccine.

A Aase1, E A Høiby, T E Michaelsen.   

Abstract

To study how the different immunoglobulin (Ig)G subclass antibodies may confer protection against systemic meningococcal disease, we isolated IgG1, IgG2 and IgG3 antibodies from plasma from vaccinees immunized with the Norwegian meningococcal outer membrane vesicle vaccine. Four IgG1, one IgG2 and four IgG3 preparations were purified. The IgG2 and IgG3 subclass preparations were free from contaminating subclasses, whereas the IgG1 preparations contained from 0 to 14% of IgG2 and/or IgG3. Immunoblotting against whole-cell meningococcal antigens showed broad specificities of the various preparations, both within and between subclasses. These subclass preparations were tested for opsonophagocytic and bactericidal activity. As targets we used two different variants of the meningococcal vaccine strain, with low (44/76-SL) and high (44/76-1) expression of the outer membrane protein Opc. Using polymorphonuclear leucocytes as effector cells in the presence of human complement, all three IgG subclass preparations revealed high, and similar, opsonophagocytic activities against 44/76-SL, whereas against 44/76-1 the IgG2 preparation showed a reduced activity and most IgG3 preparations were slightly more active than the IgG1 preparations. Regarding bactericidal activity, all the three subclasses were highly active against 44/76-SL. Against 44/76-1 the bactericidal activities were somewhat more varied: all IgG1 and three IgG3 preparations exhibited higher activities than against 44/76-SL. Due to the low concentration in the IgG2 preparations, only a weak activity was seen against 44/76-1. One IgG3 preparation that was highly opsonophagocytic revealed no bactericidal activity against either of the two bacterial variants examined. In conclusion, we have shown that the IgG subclass effector functions differ from person to person, but that antibodies of IgG1, IgG2 and IgG3 subclasses, judged by their behaviour in the functional tests, may all contribute to protection against meningococcal disease.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9600322     DOI: 10.1046/j.1365-3083.1998.00319.x

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  9 in total

1.  Human opsonins induced during meningococcal disease recognize outer membrane proteins PorA and PorB.

Authors:  A K Lehmann; A Halstensen; I S Aaberge; J Holst; T E Michaelsen; S Sornes; L M Wetzler; H Guttormsen
Journal:  Infect Immun       Date:  1999-05       Impact factor: 3.441

2.  Construction and functional activities of chimeric mouse-human immunoglobulin G and immunoglobulin M antibodies against the Neisseria meningitidis PorA P1.7 and P1.16 epitopes.

Authors:  Terje E Michaelsen; Øistein Ihle; Karen Johanne Beckstrøm; Tove K Herstad; Jan Kolberg; E Arne Høiby; Audun Aase
Journal:  Infect Immun       Date:  2003-10       Impact factor: 3.441

3.  Opsonophagocytic activity and other serological indications of Bordetella pertussis infection in military recruits in Norway.

Authors:  Audun Aase; Tove Karin Herstad; Samuel Merino; Kari Torkildsen Brandsdal; Bjørn Peter Berdal; Erja M Aleksandersen; Ingeborg S Aaberge
Journal:  Clin Vaccine Immunol       Date:  2007-05-16

4.  Functional and specific antibody responses in adult volunteers in new zealand who were given one of two different meningococcal serogroup B outer membrane vesicle vaccines.

Authors:  E Wedege; K Bolstad; A Aase; T K Herstad; L McCallum; E Rosenqvist; P Oster; D Martin
Journal:  Clin Vaccine Immunol       Date:  2007-05-09

5.  Protection by natural human immunoglobulin M antibody to meningococcal serogroup B capsular polysaccharide in the infant rat protection assay is independent of complement-mediated bacterial lysis.

Authors:  Maija Toropainen; Leena Saarinen; Elisabeth Wedege; Karin Bolstad; Terje E Michaelsen; Audun Aase; Helena Käyhty
Journal:  Infect Immun       Date:  2005-08       Impact factor: 3.441

6.  Understanding the immune responses to the meningococcal strain-specific vaccine MeNZB measured in studies of infants.

Authors:  N Ruijne; R A Lea; J O'Hallahan; P Oster; D Martin
Journal:  Clin Vaccine Immunol       Date:  2006-07

7.  Functional activities and immunoglobulin variable regions of human and murine monoclonal antibodies specific for the P1.7 PorA protein loop of Neisseria meningitidis.

Authors:  J Wang; G A Jarvis; M Achtman; E Rosenqvist; T E Michaelsen; A Aase; J M Griffiss
Journal:  Infect Immun       Date:  2000-04       Impact factor: 3.441

8.  Investigation into the Antigenic Properties and Contributions to Growth in Blood of the Meningococcal Haemoglobin Receptors, HpuAB and HmbR.

Authors:  Fadil A Bidmos; Hannah Chan; Uta Praekelt; Isfahan Tauseef; Youssif M Ali; Edward B Kaczmarski; Ian Feavers; Christopher D Bayliss
Journal:  PLoS One       Date:  2015-07-24       Impact factor: 3.240

9.  In silico studies of outer membrane of Neisseria meningitidis por a: its expression and immunogenic properties.

Authors:  Ava Behrouzi; Saeid Bouzari; Seyed Davar Siadat; Shiva Irani
Journal:  Int J Mol Cell Med       Date:  2014
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.